Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2024-2030

Page: 114

Published Date: 14 Feb 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Community-acquired Bacterial Pneumonia market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.

This report studies the global Community-acquired Bacterial Pneumonia demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Community-acquired Bacterial Pneumonia, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Community-acquired Bacterial Pneumonia that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Community-acquired Bacterial Pneumonia total market, 2019-2030, (USD Million)
Global Community-acquired Bacterial Pneumonia total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Community-acquired Bacterial Pneumonia total market, key domestic companies and share, (USD Million)
Global Community-acquired Bacterial Pneumonia revenue by player and market share 2019-2024, (USD Million)
Global Community-acquired Bacterial Pneumonia total market by Type, CAGR, 2019-2030, (USD Million)
Global Community-acquired Bacterial Pneumonia total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Community-acquired Bacterial Pneumonia market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc, Bayer AG, Lupin Pharmaceuticals, Mylan N.V., Sanofi S.A. and Pfizer Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Community-acquired Bacterial Pneumonia market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Community-acquired Bacterial Pneumonia Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Community-acquired Bacterial Pneumonia Market, Segmentation by Type
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others

Global Community-acquired Bacterial Pneumonia Market, Segmentation by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Companies Profiled:
Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG

Key Questions Answered
1. How big is the global Community-acquired Bacterial Pneumonia market?
2. What is the demand of the global Community-acquired Bacterial Pneumonia market?
3. What is the year over year growth of the global Community-acquired Bacterial Pneumonia market?
4. What is the total value of the global Community-acquired Bacterial Pneumonia market?
5. Who are the major players in the global Community-acquired Bacterial Pneumonia market?

Table of Contents

1 Supply Summary
    1.1 Community-acquired Bacterial Pneumonia Introduction
    1.2 World Community-acquired Bacterial Pneumonia Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Community-acquired Bacterial Pneumonia Total Market by Region (by Headquarter Location)
        1.3.1 World Community-acquired Bacterial Pneumonia Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Community-acquired Bacterial Pneumonia Market Size (2019-2030)
        1.3.3 China Community-acquired Bacterial Pneumonia Market Size (2019-2030)
        1.3.4 Europe Community-acquired Bacterial Pneumonia Market Size (2019-2030)
        1.3.5 Japan Community-acquired Bacterial Pneumonia Market Size (2019-2030)
        1.3.6 South Korea Community-acquired Bacterial Pneumonia Market Size (2019-2030)
        1.3.7 ASEAN Community-acquired Bacterial Pneumonia Market Size (2019-2030)
        1.3.8 India Community-acquired Bacterial Pneumonia Market Size (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Community-acquired Bacterial Pneumonia Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Community-acquired Bacterial Pneumonia Major Market Trends

2 Demand Summary
    2.1 World Community-acquired Bacterial Pneumonia Consumption Value (2019-2030)
    2.2 World Community-acquired Bacterial Pneumonia Consumption Value by Region
        2.2.1 World Community-acquired Bacterial Pneumonia Consumption Value by Region (2019-2024)
        2.2.2 World Community-acquired Bacterial Pneumonia Consumption Value Forecast by Region (2025-2030)
    2.3 United States Community-acquired Bacterial Pneumonia Consumption Value (2019-2030)
    2.4 China Community-acquired Bacterial Pneumonia Consumption Value (2019-2030)
    2.5 Europe Community-acquired Bacterial Pneumonia Consumption Value (2019-2030)
    2.6 Japan Community-acquired Bacterial Pneumonia Consumption Value (2019-2030)
    2.7 South Korea Community-acquired Bacterial Pneumonia Consumption Value (2019-2030)
    2.8 ASEAN Community-acquired Bacterial Pneumonia Consumption Value (2019-2030)
    2.9 India Community-acquired Bacterial Pneumonia Consumption Value (2019-2030)

3 World Community-acquired Bacterial Pneumonia Companies Competitive Analysis
    3.1 World Community-acquired Bacterial Pneumonia Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Community-acquired Bacterial Pneumonia Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Community-acquired Bacterial Pneumonia in 2023
        3.2.3 Global Concentration Ratios (CR8) for Community-acquired Bacterial Pneumonia in 2023
    3.3 Community-acquired Bacterial Pneumonia Company Evaluation Quadrant
    3.4 Community-acquired Bacterial Pneumonia Market: Overall Company Footprint Analysis
        3.4.1 Community-acquired Bacterial Pneumonia Market: Region Footprint
        3.4.2 Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
        3.4.3 Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Community-acquired Bacterial Pneumonia Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Community-acquired Bacterial Pneumonia Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Community-acquired Bacterial Pneumonia Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Community-acquired Bacterial Pneumonia Consumption Value Comparison
        4.2.1 United States VS China: Community-acquired Bacterial Pneumonia Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Community-acquired Bacterial Pneumonia Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Community-acquired Bacterial Pneumonia Companies and Market Share, 2019-2024
        4.3.1 United States Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Community-acquired Bacterial Pneumonia Revenue, (2019-2024)
    4.4 China Based Companies Community-acquired Bacterial Pneumonia Revenue and Market Share, 2019-2024
        4.4.1 China Based Community-acquired Bacterial Pneumonia Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Community-acquired Bacterial Pneumonia Revenue, (2019-2024)
    4.5 Rest of World Based Community-acquired Bacterial Pneumonia Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Community-acquired Bacterial Pneumonia Revenue, (2019-2024)

5 Market Analysis by Type
    5.1 World Community-acquired Bacterial Pneumonia Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Pleuromutilin Antibiotic
        5.2.2 Cephalosporin
        5.2.3 Glycylcycline
        5.2.4 Oxazolidinone
        5.2.5 Ketolide
        5.2.6 Others
    5.3 Market Segment by Type
        5.3.1 World Community-acquired Bacterial Pneumonia Market Size by Type (2019-2024)
        5.3.2 World Community-acquired Bacterial Pneumonia Market Size by Type (2025-2030)
        5.3.3 World Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Community-acquired Bacterial Pneumonia Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Hospital Pharmacies
        6.2.2 Retail Pharmacies
        6.2.3 Online Pharmacies
    6.3 Market Segment by Application
        6.3.1 World Community-acquired Bacterial Pneumonia Market Size by Application (2019-2024)
        6.3.2 World Community-acquired Bacterial Pneumonia Market Size by Application (2025-2030)
        6.3.3 World Community-acquired Bacterial Pneumonia Market Size by Application (2019-2030)

7 Company Profiles
    7.1 Nabriva Therapeutics
        7.1.1 Nabriva Therapeutics Details
        7.1.2 Nabriva Therapeutics Major Business
        7.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Services
        7.1.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Nabriva Therapeutics Recent Developments/Updates
        7.1.6 Nabriva Therapeutics Competitive Strengths & Weaknesses
    7.2 Paratek Pharmaceuticals
        7.2.1 Paratek Pharmaceuticals Details
        7.2.2 Paratek Pharmaceuticals Major Business
        7.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
        7.2.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 Paratek Pharmaceuticals Recent Developments/Updates
        7.2.6 Paratek Pharmaceuticals Competitive Strengths & Weaknesses
    7.3 Melinta Therapeutics
        7.3.1 Melinta Therapeutics Details
        7.3.2 Melinta Therapeutics Major Business
        7.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Services
        7.3.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Melinta Therapeutics Recent Developments/Updates
        7.3.6 Melinta Therapeutics Competitive Strengths & Weaknesses
    7.4 Allergan plc
        7.4.1 Allergan plc Details
        7.4.2 Allergan plc Major Business
        7.4.3 Allergan plc Community-acquired Bacterial Pneumonia Product and Services
        7.4.4 Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 Allergan plc Recent Developments/Updates
        7.4.6 Allergan plc Competitive Strengths & Weaknesses
    7.5 Bayer AG
        7.5.1 Bayer AG Details
        7.5.2 Bayer AG Major Business
        7.5.3 Bayer AG Community-acquired Bacterial Pneumonia Product and Services
        7.5.4 Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 Bayer AG Recent Developments/Updates
        7.5.6 Bayer AG Competitive Strengths & Weaknesses
    7.6 Lupin Pharmaceuticals
        7.6.1 Lupin Pharmaceuticals Details
        7.6.2 Lupin Pharmaceuticals Major Business
        7.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
        7.6.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 Lupin Pharmaceuticals Recent Developments/Updates
        7.6.6 Lupin Pharmaceuticals Competitive Strengths & Weaknesses
    7.7 Mylan N.V.
        7.7.1 Mylan N.V. Details
        7.7.2 Mylan N.V. Major Business
        7.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Product and Services
        7.7.4 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 Mylan N.V. Recent Developments/Updates
        7.7.6 Mylan N.V. Competitive Strengths & Weaknesses
    7.8 Sanofi S.A.
        7.8.1 Sanofi S.A. Details
        7.8.2 Sanofi S.A. Major Business
        7.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Services
        7.8.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 Sanofi S.A. Recent Developments/Updates
        7.8.6 Sanofi S.A. Competitive Strengths & Weaknesses
    7.9 Pfizer Inc.
        7.9.1 Pfizer Inc. Details
        7.9.2 Pfizer Inc. Major Business
        7.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Services
        7.9.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 Pfizer Inc. Recent Developments/Updates
        7.9.6 Pfizer Inc. Competitive Strengths & Weaknesses
    7.10 Dainippon Sumitomo Pharma
        7.10.1 Dainippon Sumitomo Pharma Details
        7.10.2 Dainippon Sumitomo Pharma Major Business
        7.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Services
        7.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 Dainippon Sumitomo Pharma Recent Developments/Updates
        7.10.6 Dainippon Sumitomo Pharma Competitive Strengths & Weaknesses
    7.11 Takeda Pharmaceutical Company Limited
        7.11.1 Takeda Pharmaceutical Company Limited Details
        7.11.2 Takeda Pharmaceutical Company Limited Major Business
        7.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Services
        7.11.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
        7.11.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
    7.12 Basilea Pharmaceutica International AG
        7.12.1 Basilea Pharmaceutica International AG Details
        7.12.2 Basilea Pharmaceutica International AG Major Business
        7.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Services
        7.12.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 Basilea Pharmaceutica International AG Recent Developments/Updates
        7.12.6 Basilea Pharmaceutica International AG Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Community-acquired Bacterial Pneumonia Industry Chain
    8.2 Community-acquired Bacterial Pneumonia Upstream Analysis
    8.3 Community-acquired Bacterial Pneumonia Midstream Analysis
    8.4 Community-acquired Bacterial Pneumonia Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Community-acquired Bacterial Pneumonia Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
    Table 2. World Community-acquired Bacterial Pneumonia Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
    Table 3. World Community-acquired Bacterial Pneumonia Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
    Table 4. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2019-2024), (by Headquarter Location)
    Table 5. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2025-2030), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Community-acquired Bacterial Pneumonia Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
    Table 8. World Community-acquired Bacterial Pneumonia Consumption Value by Region (2019-2024) & (USD Million)
    Table 9. World Community-acquired Bacterial Pneumonia Consumption Value Forecast by Region (2025-2030) & (USD Million)
    Table 10. World Community-acquired Bacterial Pneumonia Revenue by Player (2019-2024) & (USD Million)
    Table 11. Revenue Market Share of Key Community-acquired Bacterial Pneumonia Players in 2023
    Table 12. World Community-acquired Bacterial Pneumonia Industry Rank of Major Player, Based on Revenue in 2023
    Table 13. Global Community-acquired Bacterial Pneumonia Company Evaluation Quadrant
    Table 14. Head Office of Key Community-acquired Bacterial Pneumonia Player
    Table 15. Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
    Table 16. Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
    Table 17. Community-acquired Bacterial Pneumonia Mergers & Acquisitions Activity
    Table 18. United States VS China Community-acquired Bacterial Pneumonia Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 19. United States VS China Community-acquired Bacterial Pneumonia Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 20. United States Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Community-acquired Bacterial Pneumonia Revenue, (2019-2024) & (USD Million)
    Table 22. United States Based Companies Community-acquired Bacterial Pneumonia Revenue Market Share (2019-2024)
    Table 23. China Based Community-acquired Bacterial Pneumonia Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Community-acquired Bacterial Pneumonia Revenue, (2019-2024) & (USD Million)
    Table 25. China Based Companies Community-acquired Bacterial Pneumonia Revenue Market Share (2019-2024)
    Table 26. Rest of World Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Community-acquired Bacterial Pneumonia Revenue, (2019-2024) & (USD Million)
    Table 28. Rest of World Based Companies Community-acquired Bacterial Pneumonia Revenue Market Share (2019-2024)
    Table 29. World Community-acquired Bacterial Pneumonia Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Table 30. World Community-acquired Bacterial Pneumonia Market Size by Type (2019-2024) & (USD Million)
    Table 31. World Community-acquired Bacterial Pneumonia Market Size by Type (2025-2030) & (USD Million)
    Table 32. World Community-acquired Bacterial Pneumonia Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Table 33. World Community-acquired Bacterial Pneumonia Market Size by Application (2019-2024) & (USD Million)
    Table 34. World Community-acquired Bacterial Pneumonia Market Size by Application (2025-2030) & (USD Million)
    Table 35. Nabriva Therapeutics Basic Information, Area Served and Competitors
    Table 36. Nabriva Therapeutics Major Business
    Table 37. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Services
    Table 38. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 39. Nabriva Therapeutics Recent Developments/Updates
    Table 40. Nabriva Therapeutics Competitive Strengths & Weaknesses
    Table 41. Paratek Pharmaceuticals Basic Information, Area Served and Competitors
    Table 42. Paratek Pharmaceuticals Major Business
    Table 43. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
    Table 44. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 45. Paratek Pharmaceuticals Recent Developments/Updates
    Table 46. Paratek Pharmaceuticals Competitive Strengths & Weaknesses
    Table 47. Melinta Therapeutics Basic Information, Area Served and Competitors
    Table 48. Melinta Therapeutics Major Business
    Table 49. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Services
    Table 50. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 51. Melinta Therapeutics Recent Developments/Updates
    Table 52. Melinta Therapeutics Competitive Strengths & Weaknesses
    Table 53. Allergan plc Basic Information, Area Served and Competitors
    Table 54. Allergan plc Major Business
    Table 55. Allergan plc Community-acquired Bacterial Pneumonia Product and Services
    Table 56. Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 57. Allergan plc Recent Developments/Updates
    Table 58. Allergan plc Competitive Strengths & Weaknesses
    Table 59. Bayer AG Basic Information, Area Served and Competitors
    Table 60. Bayer AG Major Business
    Table 61. Bayer AG Community-acquired Bacterial Pneumonia Product and Services
    Table 62. Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 63. Bayer AG Recent Developments/Updates
    Table 64. Bayer AG Competitive Strengths & Weaknesses
    Table 65. Lupin Pharmaceuticals Basic Information, Area Served and Competitors
    Table 66. Lupin Pharmaceuticals Major Business
    Table 67. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
    Table 68. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 69. Lupin Pharmaceuticals Recent Developments/Updates
    Table 70. Lupin Pharmaceuticals Competitive Strengths & Weaknesses
    Table 71. Mylan N.V. Basic Information, Area Served and Competitors
    Table 72. Mylan N.V. Major Business
    Table 73. Mylan N.V. Community-acquired Bacterial Pneumonia Product and Services
    Table 74. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 75. Mylan N.V. Recent Developments/Updates
    Table 76. Mylan N.V. Competitive Strengths & Weaknesses
    Table 77. Sanofi S.A. Basic Information, Area Served and Competitors
    Table 78. Sanofi S.A. Major Business
    Table 79. Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Services
    Table 80. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 81. Sanofi S.A. Recent Developments/Updates
    Table 82. Sanofi S.A. Competitive Strengths & Weaknesses
    Table 83. Pfizer Inc. Basic Information, Area Served and Competitors
    Table 84. Pfizer Inc. Major Business
    Table 85. Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Services
    Table 86. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 87. Pfizer Inc. Recent Developments/Updates
    Table 88. Pfizer Inc. Competitive Strengths & Weaknesses
    Table 89. Dainippon Sumitomo Pharma Basic Information, Area Served and Competitors
    Table 90. Dainippon Sumitomo Pharma Major Business
    Table 91. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Services
    Table 92. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 93. Dainippon Sumitomo Pharma Recent Developments/Updates
    Table 94. Dainippon Sumitomo Pharma Competitive Strengths & Weaknesses
    Table 95. Takeda Pharmaceutical Company Limited Basic Information, Area Served and Competitors
    Table 96. Takeda Pharmaceutical Company Limited Major Business
    Table 97. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Services
    Table 98. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 99. Takeda Pharmaceutical Company Limited Recent Developments/Updates
    Table 100. Basilea Pharmaceutica International AG Basic Information, Area Served and Competitors
    Table 101. Basilea Pharmaceutica International AG Major Business
    Table 102. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Services
    Table 103. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 104. Global Key Players of Community-acquired Bacterial Pneumonia Upstream (Raw Materials)
    Table 105. Community-acquired Bacterial Pneumonia Typical Customers
List of Figure
    Figure 1. Community-acquired Bacterial Pneumonia Picture
    Figure 2. World Community-acquired Bacterial Pneumonia Total Market Size: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Community-acquired Bacterial Pneumonia Total Market Size (2019-2030) & (USD Million)
    Figure 4. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
    Figure 5. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2019-2030), (by Headquarter Location)
    Figure 6. United States Based Company Community-acquired Bacterial Pneumonia Revenue (2019-2030) & (USD Million)
    Figure 7. China Based Company Community-acquired Bacterial Pneumonia Revenue (2019-2030) & (USD Million)
    Figure 8. Europe Based Company Community-acquired Bacterial Pneumonia Revenue (2019-2030) & (USD Million)
    Figure 9. Japan Based Company Community-acquired Bacterial Pneumonia Revenue (2019-2030) & (USD Million)
    Figure 10. South Korea Based Company Community-acquired Bacterial Pneumonia Revenue (2019-2030) & (USD Million)
    Figure 11. ASEAN Based Company Community-acquired Bacterial Pneumonia Revenue (2019-2030) & (USD Million)
    Figure 12. India Based Company Community-acquired Bacterial Pneumonia Revenue (2019-2030) & (USD Million)
    Figure 13. Community-acquired Bacterial Pneumonia Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 16. World Community-acquired Bacterial Pneumonia Consumption Value Market Share by Region (2019-2030)
    Figure 17. United States Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 18. China Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 20. Japan Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 21. South Korea Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 22. ASEAN Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 23. India Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 24. Producer Shipments of Community-acquired Bacterial Pneumonia by Player Revenue ($MM) and Market Share (%): 2023
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Community-acquired Bacterial Pneumonia Markets in 2023
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Community-acquired Bacterial Pneumonia Markets in 2023
    Figure 27. United States VS China: Community-acquired Bacterial Pneumonia Revenue Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Community-acquired Bacterial Pneumonia Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. World Community-acquired Bacterial Pneumonia Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Figure 30. World Community-acquired Bacterial Pneumonia Market Size Market Share by Type in 2023
    Figure 31. Pleuromutilin Antibiotic
    Figure 32. Cephalosporin
    Figure 33. Glycylcycline
    Figure 34. Oxazolidinone
    Figure 35. Ketolide
    Figure 36. Others
    Figure 37. World Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2019-2030)
    Figure 38. World Community-acquired Bacterial Pneumonia Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Figure 39. World Community-acquired Bacterial Pneumonia Market Size Market Share by Application in 2023
    Figure 40. Hospital Pharmacies
    Figure 41. Retail Pharmacies
    Figure 42. Online Pharmacies
    Figure 43. Community-acquired Bacterial Pneumonia Industrial Chain
    Figure 44. Methodology
    Figure 45. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG

Related Reports

Global Community-acquired Bacterial Pneumonia Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Community-acquired Bacterial Pneumonia Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 08 Jan 2023

date Pharma & Healthcare

Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2023-2029

Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2023-2029

date 20 Feb 2023

date Pharma & Healthcare

The global Community-acquired Bacterial Pneumonia market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Community-acquired Bacterial Pneumonia Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Community-acquired Bacterial Pneumonia Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 12 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Community-acquired Bacterial Pneumonia market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

Community-acquired Bacterial Pneumonia

Community Acquired Bacterial Pneumonia(CABP) Therapeutics

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>